ALN-4915 Phase 1 Trial, Healthy Volunteers

Alnylam Pharmaceuticals registered a Phase 1 clinical trial for ALN-4915 on ClinicalTrials.gov. The study aims to evaluate safety, tolerability, pharmacodynamics, and pharmacokinetics of ALN-4915 in approximately 60 adult healthy volunteers receiving the drug or placebo.

For compliance and regulatory professionals, this trial registration indicates Alnylam is advancing ALN-4915 into human testing. While this is an informational registry entry rather than a regulatory action, it signals the drug candidate has completed preclinical development and received necessary approvals to proceed to first-in-human studies.